<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AZASITE- azithromycin monohydrate solution/ drops </strong><br>Akorn, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use AzaSite safely and effectively. See full prescribing information for AzaSite.<br>AzaSite<span class="Sup">®</span> (azithromycin ophthalmic solution) 1%<br>Sterile topical ophthalmic drops <br>Initial U.S. Approval: 2007
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Contraindications (<a href="#s4">4</a>)  07/2012
 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">AzaSite is a macrolide antibiotic indicated for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by susceptible isolates of the following microorganisms: CDC coryneform group G, <span class="Italics">Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis</span> group, and <span class="Italics">Streptococcus pneumoniae.</span> (<a href="#s1">1</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Instill 1 drop in the affected eye(s) twice daily, eight to twelve hours apart for the first two days and then instill 1 drop in the affected eye(s) once daily for the next five days. (<a href="#s2">2</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">2.5 mL of 1% sterile topical ophthalmic solution. (<a href="#s3">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#s4">4</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Square">
<li>For topical ophthalmic use only. (<a href="#s6">5.1</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have been reported with systemic use of azithromycin. (<a href="#s7">5.2</a>)
</li>
<li>Growth of resistant organisms may occur with prolonged use. (<a href="#s8">5.3</a>)
</li>
<li>Patients should not wear contact lenses if they have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. (<a href="#s10">5.4</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reaction reported in patients was <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span> (1-2% of patients). (<a href="#s11">6</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Akorn,  Inc. at 1-800-932-5676 or FDA at  1-800-FDA-1088 or </span><span class="Bold Underline">www.fda.gov/medwatch</span><span class="Bold">.</span> </p>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 11/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc"><span class="XmChange"></span>4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Topical Ophthalmic Use Only
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> with Systemic Use of Azithromycin
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Growth of Resistant Organisms with Prolonged Use
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Avoidance of Contact Lenses
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics
</a></h2>
<h2><a href="#section-9.3" class="toc">12.4 Microbiology
</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h2><a href="#section-10.2" class="toc">13.2 Animal Toxicology and/or Pharmacology
</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First"> AzaSite<span class="Sup">®</span> is indicated for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by susceptible isolates of the following microorganisms:
</p>
<dl>
<dt> 
</dt>
<dd>CDC coryneform group G*
</dd>
<dt> 
</dt>
<dd><span class="Italics">Haemophilus influenzae</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Staphylococcus aureus</span></dd>
<dt> 
</dt>
<dd>
<span class="Italics">Streptococcus mitis</span> group
</dd>
<dt> 
</dt>
<dd><span class="Italics">Streptococcus pneumoniae</span></dd>
<dt> 
</dt>
<dd><span class="Italics">* Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First"> The recommended dosage regimen for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> is:
</p>
<p> Instill 1 drop in the affected eye(s) twice daily, eight to twelve hours apart for the first two days and then instill 1 drop in the affected eye(s) once daily for the next five days.
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First"> 2.5 mL of a 1% sterile topical ophthalmic solution.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1 style="border-left:1px solid;">
<span class="XmChange"></span>4 CONTRAINDICATIONS
</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product.
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Topical Ophthalmic Use Only
</h2>
<p class="First"> NOT FOR INJECTION. AzaSite is indicated for topical ophthalmic use only, and should not be administered systemically, injected subconjunctivally, or introduced directly into the anterior chamber of the eye.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> with Systemic Use of Azithromycin
</h2>
<p class="First"> In patients receiving systemically administered azithromycin, serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and dermatologic reactions including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported rarely in patients on azithromycin therapy. Although rare, fatalities have been reported. The potential for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> should be considered based on known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to azithromycin when administered systemically.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Growth of Resistant Organisms with Prolonged Use
</h2>
<p class="First"> As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If super-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and where appropriate, fluorescein staining.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Avoidance of Contact Lenses
</h2>
<p class="First"> Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s11"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First"> Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with the rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.
</p>
<p> The data described below reflect exposure to AzaSite in 698 patients. The population was between 1 and 87 years old with clinical signs and symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. The most frequently reported ocular adverse reaction reported in patients receiving AzaSite was <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>. This reaction occurred in approximately 1-2% of patients. Other adverse reactions associated with the use of AzaSite were reported in less than 1% of patients and included ocular reactions (<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> and irritation upon instillation, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, ocular discharge, <span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">punctate keratitis</span>, visual acuity reduction) and non-ocular reactions (<span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, periocular <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>).
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s12"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s13"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<p class="First"> Pregnancy Category B. Reproduction studies have been performed in rats and mice at doses up to 200 mg/kg/day. The highest dose was associated with moderate maternal toxicity. These doses are estimated to be approximately 5,000 times the maximum human ocular daily dose of 2 mg. In the animal studies, no evidence of harm to the fetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s14"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First"> It is not known whether azithromycin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when azithromycin is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s15"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First"> The safety and effectiveness of AzaSite solution in pediatric patients below 1 year of age have not been established. The efficacy of AzaSite in treating bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> in pediatric patients one year or older has been demonstrated in controlled clinical trials <span class="Italics">[see Clinical Studies (<a href="#s25">14</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s16"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First"> No overall differences in safety or effectiveness have been observed between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s17"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First"> AzaSite (azithromycin ophthalmic solution) is a 1% sterile aqueous topical ophthalmic solution of azithromycin formulated in DuraSite<span class="Sup">®</span> (polycarbophil, edetate disodium, sodium chloride). AzaSite is an off-white, viscous liquid with an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 290 mOsm/kg.
</p>
<p><span class="Bold">Preservative:</span> 0.003% benzalkonium chloride. <span class="Bold">Inactives:</span> mannitol, citric acid, sodium citrate, poloxamer 407, polycarbophil, edetate disodium (EDTA), sodium chloride, water for injection, and sodium hydroxide to adjust pH to 6.3.
</p>
<p> Azithromycin is a macrolide antibiotic with a 15-membered ring. Its chemical name is (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]1-oxa-6-aza-cyclopentadecan-15-one, and the structural formula is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=14ae4c07-b042-452a-b069-2b41bc646e04&amp;name=aza00-0000-01.jpg">
</div>
<p> Azithromycin has a molecular weight of 749, and its empirical formula is C<span class="Sub">38</span>H<span class="Sub">72</span>N<span class="Sub">2</span>O<span class="Sub">12</span>.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s18"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s19"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First"> Azithromycin is a macrolide antibiotic <span class="Italics">[see Clinical Pharmacology (<a href="#s21">12.4</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s20"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First"> The plasma concentration of azithromycin following ocular administration of AzaSite (azithromycin ophthalmic solution) in humans is unknown. Based on the proposed dose of one drop to each eye (total dose of 100 mcL or 1 mg) and exposure information from systemic administration, the systemic concentration of azithromycin following ocular administration is estimated to be below quantifiable limits (≤10 ng/mL) at steady-state in humans, assuming 100% systemic availability.
</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="s21"></a><a name="section-9.3"></a><p></p>
<h2>12.4 Microbiology
</h2>
<p class="First"> Azithromycin acts by binding to the 50S ribosomal subunit of susceptible microorganisms and interfering with microbial protein synthesis.
</p>
<p> Azithromycin has been shown to be active against most isolates of the following microorganisms, both <span class="Italics">in vitro</span> and clinically in conjunctival <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> <span class="Italics">[see Indications and Usage (<a href="#s1">1</a>)]</span>.
</p>
<dl>
<dt> 
</dt>
<dd>CDC coryneform group G* 
</dd>
<dt> 
</dt>
<dd><span class="Italics">Haemophilus influenzae</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Staphylococcus aureus</span></dd>
<dt> 
</dt>
<dd>
<span class="Italics">Streptococcus mitis</span> group
</dd>
<dt> 
</dt>
<dd><span class="Italics">Streptococcus pneumoniae</span></dd>
<dt> 
</dt>
<dd>* <span class="Italics">Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span>
</dd>
</dl>
<p> The following <span class="Italics">in vitro</span> data are also available, <span class="Bold">but their clinical significance in ophthalmic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is unknown.</span> The safety and effectiveness of AzaSite in treating ophthalmological <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established.
</p>
<p> The following microorganisms are considered susceptible when evaluated using systemic break points. However, a correlation between the <span class="Italics">in vitro</span> systemic breakpoint and ophthalmological efficacy has not been established. This list of microorganisms is provided as an aid only in assessing the potential treatment of conjunctival <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Azithromycin exhibits <span class="Italics">in vitro</span> minimal inhibitory concentrations (MICs) of equal or less (systemic susceptible breakpoint) against most (≥90%) of isolates of the following ocular pathogens:
</p>
<dl>
<dt> 
</dt>
<dd><span class="Italics">Chlamydia pneumoniae</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Chlamydia trachomatis</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Legionella pneumophila</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Moraxella catarrhalis</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Mycoplasma hominis</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Mycoplasma pneumoniae</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Neisseria gonorrhoeae</span></dd>
<dt> 
</dt>
<dd>
<span class="Italics">Peptostreptococcus</span> species
</dd>
<dt> 
</dt>
<dd>Streptococci (Groups C, F, G) 
</dd>
<dt> 
</dt>
<dd><span class="Italics">Streptococcus pyogenes</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Streptococcus agalactiae</span></dd>
<dt> 
</dt>
<dd><span class="Italics">Ureaplasma urealyticum</span></dd>
<dt> 
</dt>
<dd>Viridans group streptococci
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s22"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s23"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First"> Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no mutagenic potential in standard laboratory tests: mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, human lymphocyte clastogenic assay, and mouse bone marrow clastogenic assay. No evidence of impaired fertility due to azithromycin was found in mice or rats that received oral doses of up to 200 mg/kg/day.
</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="s24"></a><a name="section-10.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology
</h2>
<p class="First"> Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of mice, rats, and dogs given multiple systemic doses of azithromycin. Cytoplasmic microvacuolation, which is likely a manifestation of phospholipidosis, has been observed in the corneas of rabbits given multiple ocular doses of AzaSite. This effect was reversible upon cessation of AzaSite treatment. The significance of this toxicological finding for animals and for humans is unknown.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s25"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First"> In a randomized, vehicle-controlled, double-blind, multicenter clinical study in which patients were dosed twice daily for the first two days, then once daily on days 3, 4, and 5, AzaSite solution was superior to vehicle on days 6-7 in patients who had a confirmed clinical diagnosis of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. Clinical resolution was achieved in 63% (82/130) of patients treated with AzaSite versus 50% (74/149) of patients treated with vehicle. The p-value for the comparison was 0.03 and the 95% confidence interval around the 13% (63%-50%) difference was 2% to 25%. The microbiological success rate for the eradication of the baseline pathogens was approximately 88% compared to 66% of patients treated with vehicle (p&lt;0.001, confidence interval around the 22% difference was 13% to 31%). Microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s26"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First"> AzaSite is a sterile aqueous topical ophthalmic formulation of 1% azithromycin.
</p>
<p> NDC 17478-307-03: 2.5 mL in 5 mL bottle containing a total of 25 mg of azithromycin in a white, round, low-density polyethylene (LDPE) bottle, with a clear LDPE dropper tip, and a tan colored high density polyethylene (HDPE) eyedropper cap. A white tamper evident over-cap is provided.
</p>
<p> NDC 17478-307-04: 2.5 mL in 4 mL bottle containing a total of 25 mg of azithromycin in a white, round, low-density polyethylene (LDPE) bottle, with a clear LDPE dropper tip, and a tan colored high density polyethylene (HDPE) eyedropper cap. A white tamper evident over-cap is provided.
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s27"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Storage and Handling:</span></p>
<p> Store unopened bottle under refrigeration at 2°C to 8°C (36°F to 46°F). Once the bottle is opened, store at 2°C to 25°C (36°F to 77°F) for up to 14 days. Discard after the 14 days.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s28"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First"> See FDA-Approved Patient Labeling (<a href="#e28">Patient Information</a>).
</p>
<p> Patients should be advised to avoid contaminating the applicator tip by allowing it to touch the eye, fingers or other sources.
</p>
<p> Patients should be directed to discontinue use and contact a physician if any signs of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occur.
</p>
<p>Patients should be told that although it is common to feel better early in the course of the therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by AzaSite (azithromycin ophthalmic solution) or other antibacterial drugs in the future.
</p>
<p> Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.
</p>
<p>Patients should be advised to thoroughly wash hands prior to using AzaSite.
</p>
<p> Patients should be advised to invert the closed bottle (upside down) and shake once before each use. Remove cap with bottle still in the inverted position. Tilt head back, and with bottle inverted, gently squeeze bottle to instill one drop into the affected eye(s).
</p>
<p><span class="Bold">AKORN<br></span>Distributed by: <span class="Bold">Akorn, Inc.<br></span>Lake Forest, IL 60045
</p>
<p>U.S. Patent Nos.: 6,159,458; 6,239,113; 6,569,443; 6,861,411; 7,056,893; and Patents Pending
</p>
<p>AzaSite is a registered trademark of  InSite Vision Inc.
</p>
<p>OPZT00N      Rev. 11/13
</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="e28"></a><a name="section-14"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">AzaSite</span><span class="Bold"><span class="Sup">®</span></span> (A-zuh-site)
</p>
<p>(azithromycin ophthalmic solution) 1%
</p>
<p>Read this Patient Information before you start using AzaSite<span class="Sup">®</span> and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or treatment.
</p>
<p><span class="Bold">What is AzaSite?</span></p>
<p>AzaSite is a prescription sterile eye drop solution. AzaSite is used to treat bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> which is an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of the eye caused by certain bacteria.
</p>
<p>It is not known if AzaSite is safe and effective in children less than 1 year of age.
</p>
<p><span class="Bold">Information about bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</span></p>
<p>Bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> is a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> of the mucous membranes which line the inside of the eyelids. Symptoms may include <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the eye and discharge. The <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> can be spread to other people and to both eyes.
</p>
<p><span class="Bold">Who should not use AzaSite?</span></p>
<p><span class="Bold">Do not</span> use AzaSite if you are allergic to azithromycin or any of the ingredients in AzaSite. See the end of this Patient Information leaflet for a complete list of the ingredients in AzaSite.
</p>
<p><span class="Bold">What should I tell my doctor before using AzaSite?</span></p>
<p><span class="Bold">Before you use AzaSite, tell your doctor if you:</span></p>
<ul class="Disc">
<li>wear contact lenses. Do not wear contact lenses if you have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.
</li>
<li>are pregnant or plan to become pregnant. It is not known if AzaSite will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.
</li>
<li>are breast-feeding or plan to breast-feed. It is not known if AzaSite passes into your breast milk. Talk to your doctor about the best way to feed your baby if you are using AzaSite.
</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements.
</p>
<p>Know the medicines you take. Keep a list of them to show your doctors and pharmacist when you get a new medicine.
</p>
<p><span class="Bold">How should I use AzaSite?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Read the Instructions for Use at the end of this Patient Information</span> leaflet for the right way to use AzaSite.
</li>
<li>Use AzaSite exactly as your doctor tells you to use it.
</li>
<li>For the first 2 days place 1 drop of AzaSite in your eye (or eyes) each morning and 1 drop in your eye (or eyes) each evening. Wait 8 to 12 hours after placing your morning drops before you place evening drops in your eye (or eyes).
</li>
<li>For the next 5 days place 1 drop of AzaSite in your eye (or eyes) 1 time each day.
</li>
<li>Make sure you continue to use AzaSite as directed by your doctor even if you feel better after you start using it. Skipping drops can increase the chances that:<ul class="Circle">
<li>your medicine will not work well
</li>
<li>Bacteria can develop resistance, which means in the future your bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> may not improve from AzaSite or other drugs that treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> from bacteria.
</li>
</ul>
</li>
</ul>
<p><span class="Bold">What should I be aware of while using AzaSite?</span></p>
<p><span class="Bold">Do not</span> wear contact lenses if you have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and until you have finished your prescribed course of treatment. The symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> may include:
</p>
<ul class="Disc">
<li>discharge coming from the eye
</li>
<li><span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">eye redness</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>
</li>
</ul>
<p>Only your doctor can tell you if you have bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.
</p>
<p><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported rarely when azithromycin has been taken by mouth.</span></p>
<ul class="Disc">
<li>Serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> may occur. Azithromycin, the active ingredient in AzaSite, may cause a serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Both of these reactions may need to be treated in a hospital and may be life-threatening.
</li>
<li>Stop taking AzaSite and call your doctor right away or get emergency help if you have any of these symptoms:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, sores in your mouth, or your skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> and peels
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, eyes, lips, tongue, or throat
</li>
<li>trouble swallowing or breathing
</li>
</ul>
</li>
</ul>
<p><span class="Bold">Increased risk of other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by bacteria or fungi.</span></p>
<ul class="Disc"><li>Using AzaSite for a long time may cause other bacteria or fungi to grow. If this happens you may get a new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Tell your doctor right away if your symptoms do not get better.
</li></ul>
<p><span class="Bold">What are the possible side effects of AzaSite?</span></p>
<p>The most common side effect of AzaSite is <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>.
</p>
<p>Other side effects seen with AzaSite include:
</p>
<ul class="Disc">
<li>eye burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> and irritation when the drop hits your eye
</li>
<li>irritation on your eyelid and the skin around your eye
</li>
<li>a feeling of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and irritation or that something is in your eye
</li>
<li><span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye itching</span>
</li>
<li>discharge coming from your eye
</li>
<li>changes to the surface of your eye
</li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>
</li>
<li>changes in your taste
</li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> on your skin
</li>
<li>stuffy nose and <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> around your eye or of your face
</li>
</ul>
<p>Tell your doctor about any side effect that bothers you or that does not go away.
</p>
<p>These are not all of the possible side effects of AzaSite. For more information, ask your doctor or pharmacist.
</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">How should I store AzaSite?</span></p>
<ul class="Disc">
<li>Before you open your AzaSite, store it in the refrigerator between 36°F to 46°F (2°C to 8°C).
</li>
<li>After you open your AzaSite, store it at room temperature or the refrigerator between 36°F to 77°F (2°C to 25°C).
</li>
<li><span class="Bold">AzaSite should not be stored for more than 14 days after opening. After 14 days, throw the AzaSite bottle away.</span></li>
<li>Safely throw away medicine that is out of date or no longer needed.
</li>
</ul>
<p><span class="Bold">Keep AzaSite and all medicines out of reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of AzaSite</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use AzaSite for a condition for which it was not prescribed. Do not give AzaSite to other people, even if they have the same symptoms that you have. It may harm them.
</p>
<p>This Patient Information summarizes the most important information about AzaSite. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about AzaSite that is written for health professionals.
</p>
<p>For more information, go to <span class="Underline">www.azasite.com</span> or call 1-800-932-5676.
</p>
<p><span class="Bold">What are the ingredients in AzaSite?</span></p>
<p><span class="Bold">Active ingredient:</span> azithromycin
</p>
<p><span class="Bold">Inactive ingredients:</span> 0.003% benzalkonium chloride, mannitol, citric acid, sodium citrate, poloxamer 407, polycarbophil, edetate disodium (EDTA), sodium chloride, water, and sodium hydroxide.
</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="s29"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Instructions for Use</span></p>
<p><span class="Bold">AzaSite</span><span class="Bold"><span class="Sup">®</span></span> (A-zuh-site)
</p>
<p>(azithromycin ophthalmic solution) 1%
</p>
<p>Read this Instructions for Use for AzaSite before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or treatment.
</p>
<p><span class="Bold">Important:</span></p>
<ul class="Disc"><li><span class="Bold">AzaSite is for use as an eye drop only.</span></li></ul>
<p>The checklist below tells you when to use your medicine for each eye that has bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>:
</p>
<div class="Figure">
<a name="f02"></a><img alt="Checklist
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=14ae4c07-b042-452a-b069-2b41bc646e04&amp;name=aza00-0000-02.jpg">
</div>
<p>This is a total of 9 drops of AzaSite for each infected eye.
</p>
<ul class="Disc">
<li>Avoid letting the applicator tip touch your eye, your fingers, or other objects.
</li>
<li>If a drop misses your eye, try again.
</li>
<li>Follow the steps below to use AzaSite correctly.
</li>
</ul>
<p><span class="Bold">Before using a new bottle of AzaSite:</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Figure A
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=14ae4c07-b042-452a-b069-2b41bc646e04&amp;name=aza00-0000-03.jpg">
</div>
<ul class="Disc">
<li>Turn the white cap clockwise until it comes off. Throw away the white cap. <span class="Bold">See <a href="#f03">Figure A</a></span><div class="Figure">
<a name="f04"></a><img alt="Figure B
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=14ae4c07-b042-452a-b069-2b41bc646e04&amp;name=aza00-0000-04.jpg">
</div>
</li>
<li>Hold the bottle straight, turn the tan cap counterclockwise until it comes off. Put the tan cap back on the bottle and close tightly. (This lets out the air.) <span class="Bold">See <a href="#f04">Figure B</a></span>
</li>
</ul>
<p><span class="Bold">Wash your hands each time you use AzaSite.</span></p>
<p><span class="Bold">To use AzaSite:</span></p>
<div class="Figure">
<a name="f05"></a><img alt="Figure C
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=14ae4c07-b042-452a-b069-2b41bc646e04&amp;name=aza00-0000-05.jpg">
</div>
<p>Step 1. Turn the closed bottle upside down. <span class="Bold">See <a href="#f05">Figure C</a></span></p>
<div class="Figure">
<a name="f06"></a><img alt="Figure D
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=14ae4c07-b042-452a-b069-2b41bc646e04&amp;name=aza00-0000-06.jpg">
</div>
<p><span class="Bold">Step 2.</span> Shake your hand firmly. This helps move the medicine into the tip of the bottle. <span class="Bold">See <a href="#f06">Figure D</a></span></p>
<div class="Figure">
<a name="f07"></a><img alt="Figure E
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=14ae4c07-b042-452a-b069-2b41bc646e04&amp;name=aza00-0000-07.jpg">
</div>
<p>Step 3. Hold the bottle upside down and take off the tan cap. <span class="Bold">See <a href="#f07">Figure E</a></span></p>
<div class="Figure">
<a name="f08"></a><img alt="Figure F
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=14ae4c07-b042-452a-b069-2b41bc646e04&amp;name=aza00-0000-08.jpg">
</div>
<p>Step 4. <span class="Bold">Tilt your head back.</span> Hold the bottle over your eye and gently squeeze the bottle to let 1 drop into each eye that has bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. Put the tan cap back on the bottle and close tightly. <span class="Bold">See <a href="#f08">Figure F</a></span></p>
<p><span class="Bold">If a drop does not come out of the bottle, repeat steps one to four.</span></p>
<p><span class="Bold">This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.</span></p>
<p><span class="Bold">AKORN<br></span>Distributed by: <span class="Bold">Akorn, Inc.<br></span>Lake Forest, IL 60045
</p>
<p>U.S. Patent Nos.: 6,159,458; 6,239,113; 6,569,443; 6,861,411; 7,056,893; and Patents Pending
</p>
<p>AzaSite is a registered trademark of InSite Vision Inc.
</p>
<p>OPZTA0N Rev. 02/15
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s30"></a><a name="section-16"></a><p></p>
<p class="First">Principal Display Panel Text for Container Label:
</p>
<p>NDC 17478-307-03
</p>
<p>AzaSITE<span class="Sup">®</span></p>
<p>(azithromycin ophthalmic solution) 1%
</p>
<p>Rx Only Sterile 2.5 mL
</p>
<div class="Figure">
<a name="f09"></a><img alt="Principal Display Panel Text for Container Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=14ae4c07-b042-452a-b069-2b41bc646e04&amp;name=aza00-0000-09.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s31"></a><a name="section-17"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 17478-307-03
</p>
<p>AzaSITE<span class="Sup">®</span></p>
<p>(azithromycin ophthalmic solution) 1%
</p>
<p>Sterile 2.5 mL
</p>
<p>Rx Only
</p>
<p>FOR OPHTHALMIC USE ONLY
</p>
<div class="Figure">
<a name="f10"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=14ae4c07-b042-452a-b069-2b41bc646e04&amp;name=aza00-0000-10.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AZASITE 		
					</strong><br><span class="contentTableReg">azithromycin monohydrate solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-307</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Azithromycin Monohydrate</strong> (Azithromycin Anhydrous) </td>
<td class="formItem">Azithromycin Anhydrous</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Citric Acid Monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Poloxamer 407</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Polycarbophil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Edetate Disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Benzalkonium Chloride</strong></td>
<td class="formItem">0.03 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-307-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:17478-307-04</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:17478-307-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050810</td>
<td class="formItem">05/14/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akorn, Inc.
							(062649876)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6d3ba3c0-c4e6-415e-bca2-2d9584b9c99e</div>
<div>Set id: 14ae4c07-b042-452a-b069-2b41bc646e04</div>
<div>Version: 2</div>
<div>Effective Time: 20150310</div>
</div>
</div> <div class="DistributorName">Akorn, Inc.</div></p>
</body></html>
